M&A


  • Image attribution tooltip
    choness via Getty Images

    Medtech M&A, IPOs hit new highs as more buyers enter the space: SVB

    In a new report, Silicon Valley Bank projects that medical device mergers and acquisitions "will stay hot, as a diverse set of acquirers compete for the top deals," but sees a slowdown in initial public offering activity.

    By Jan. 14, 2022
  • Medtronic CEO: Company on track to hit guidance, omicron impact 'uncertain'

    Geoff Martha, who spoke on the opening day of J.P. Morgan's healthcare conference, said the medtech is being impacted by both the delta and omicron variants, including ongoing pressure from hospital staffing shortages.

    By Jan. 10, 2022
  • Wall Street backs Stryker-Vocera strategic fit but split on valuation

    The nearly $3 billion buy values Vocera at about 11.5 times higher than expected 2022 revenue, leading some analysts to question the overall price.

    By Updated Jan. 7, 2022
  • Image attribution tooltip
    Zhanna Hapanovich via Getty Images

    Medtech's biggest deals in 2021 and what to expect next

    After dealmaking took off last year following a 2020 lull, market watchers anticipate robust M&A ahead in 2022 as companies pursue faster growth and greater scale. 

    By Jan. 4, 2022
  • Image attribution tooltip
    Permission granted by Quidel Corporation

    Quidel to buy Ortho Clinical Diagnostics in $6B deal; stock tanks

    CEO Doug Bryant said the combined company will have a "broader geographic footprint" thanks to Ortho's reach across 130-plus countries. Quidel's shares fell by as much as 17.8% in Thursday morning trading.

    By Dec. 23, 2021
  • Cerner acquired by Oracle for $28B

    The deal further pushes Oracle into the healthcare market, where its presence is mostly in data use efficiency for payers and providers. Oracle's areas of focus include database software and cloud systems.

    By Shannon Muchmore • Dec. 21, 2021
  • Image attribution tooltip
    Permission granted by Johnson & Johnson
    Q&A

    J&J device chief on company split, omicron surge, robotic surgery

    Ashley McEvoy is confident that 2022 will not be as bad as the first or second year of the COVID-19 pandemic, even as the omicron variant drives cases up, but adds that "we're not out of the woods yet."

    By Dec. 20, 2021
  • Image attribution tooltip
    E+ via Getty Images

    Flurry of doctor group buyouts helps fuel 'extraordinary' surge in health M&A

    Companies across the healthcare spectrum are pursuing deals to strengthen operations after two years of pandemic-driven challenges, a PwC report found.

    By Dec. 14, 2021
  • Roundup: Baxter completes $10.5B Hillrom acquisition

    Wall Street analysts have questioned the price and strategic fit of the deal, which is the largest medtech buy so far in 2021.

    Dec. 14, 2021
  • Image attribution tooltip
    Permission granted by iRhythm Technologies
    Q&A

    New iRhythm CEO talks Medicare pricing, larger medtech competitors, international markets

    "I think the near-term noise is something that we'll work through, but the underlying technology has never been questioned," Quentin Blackford told MedTech Dive.

    By Nov. 19, 2021
  • Image attribution tooltip
    Photo courtesy of Stryker

    Stryker dismisses robotics threat from J&J, Zimmer with bullish forecast

    CEO Kevin Lobo said during Thursday's analyst day that the company is "poised and ready to pounce" if valuations fall as Stryker looks to leverage M&A in long-term growth plans.

    By Nov. 19, 2021
  • Siemens Healthineers projects revenue jump fueled by Varian double-digit sales growth

    The medtech expects its $16.4 billion Varian acquisition to post annual sales growth from 2023 to 2025, leading it to forecast accelerating revenue rises.

    By Nov. 17, 2021
  • Image attribution tooltip
    400tmax via Getty Images

    Globus in takeover talks with NuVasive to boost spine portfolio: reports

    Truist Securities and Piper Sandler analysts said the deal is unlikely. J.P. Morgan cautioned that earlier orthopaedic takeovers struggled to generate returns.

    By Nov. 16, 2021
  • Image attribution tooltip
    Spencer Platt via Getty Images

    BD's $2B annual M&A war chest, connected care devices at heart of growth plan

    Evercore ISI analysts said the targets and messaging were consistent with expectations, while J.P. Morgan questioned why it is taking BD longer than its peers to return margins to pre-pandemic levels.

    By Nov. 15, 2021
  • Coloplast acquires laryngectomy device maker Atos Medical in $2.5B takeover

    With Atos claiming a more than 80% share of the laryngectomy market, Coloplast sees the company as a source of growth in the coming years.

    By Nov. 10, 2021
  • Philips grows cardiac monitoring business with Cardiologs pickup

    Nearly one year after announcing its $2.8 billion acquisition of BioTelemetry, the Dutch conglomerate is further expanding its reach in remote patient monitoring with the purchase of France-based Cardiologs.

    By Nov. 9, 2021
  • Image attribution tooltip
    Mark Wilson via Getty Images

    4 takeaways from a bumper year of M&A medtech activity (so far)

    After hunkering down last year, many companies entered 2021 with large cash reserves and acquisition targets that included players lacking scale to weather the downturn.

    By Oct. 11, 2021
  • Medtechs opened 2021 with a flurry of M&A and have not stopped spending since

    With deals ranging from tuck-ins to multibillion-dollar takeovers, here's a roundup of the M&A spree so far this year after activity came to a near halt amid the unpredictability of 2020.

    Oct. 7, 2021
  • Boston Scientific inks $1.75B deal for Baylis, biggest in string of M&A

    SVB Leerink analysts wrote the acquisition will add needed support in electrophysiology and structural heart, two of the highest growth markets within cardiology. It's the medtech's fifth acquisition of 2021.

    By Oct. 6, 2021
  • Image attribution tooltip
    Courtesy of Amwell

    Digital health funding shatters record again with $21.3B so far this year

    This year, mental health is the top funded clinical indication with $3.1 billion raised, followed by digital health tools for managing cardiovascular disease, diabetes, primary care and oncology.

    By Hailey Mensik • Oct. 5, 2021
  • Amid pandemic, medtech R&D, merger activity jumped: EY report

    Research and development spending at pure-play medtechs rose to a level last seen before the 2007-2008 financial crisis.

    By Sept. 27, 2021
  • GE Healthcare to buy BK Medical for $1.45B

    The deal is aimed at expansion beyond diagnostics into surgical and therapeutic interventions, with high-single-digit return on invested capital anticipated by year five, CEO Kieran Murphy said.

    By Sept. 23, 2021
  • EU threatens Illumina for closing $8B Grail deal while still under review

    The European Commission's warning of fines and other measures is another step in a saga that could run for years. If the bloc ultimately opposes the acquisition, the path forward will be through the courts.

    By Sept. 22, 2021
  • Boston Scientific to spend $269M for remaining stake of Devoro in latest deal

    The medtech giant's 2021 M&A spree continues, following deals of $925 million for Preventice Solutions, $1.07 billion for Lumenis' surgical business and $295 million for cardiac ablation device maker Farapulse.

    By Sept. 21, 2021
  • Image attribution tooltip
    H. Armstrong Roberts via Getty Images

    Philip Morris takes control of Vectura amid pushback against acquisition

    The tobacco giant has secured investor buy-in despite continued opposition from clinicians and reports that employees of inhaled medicine specialist Vectura are concerned about the change in ownership.

    By Sept. 17, 2021